Qile Song
Research Subjects
Qile Song has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Xiaotong Feng
Shandong Key Laboratory of TCM Multi-Targets Intervention and Disease Control, the Second Affiliated Hospital of Shandong First Medical University, Taian, China
5 shared publications - Lina Feng
Department of Neurology, the Second Affiliated Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, China
3 shared publications - Mingquan Li
Department of Neurology, The Third Affiliated Clinical Hospital of Changchun University of Chinese Medicine, China
3 shared publications - Xiao-Yan Fu
School of Clinic and Basic Medicine, Shandong First Medical University, Taian 271000, China
3 shared publications - Cundong Fan
Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong Province, 271000, China
2 shared publications - Dongdong Sun
School of Life Sciences, Anhui Agricultural University, Hefei, 230036, China
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 April 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 58, 203-220
Chiral metal nanozyme-enabled SOD2 activation and siRNA delivery cooperatively mitigating chronic heart failure
Doxorubicin (DOX) treatment can lead to intracellular iron overload in cardiomyocytes, triggering excessive generation of reactive oxygen species (ROS) and resulting in cardiotoxicity. Superoxide dismutase (SOD) effectively scavenges ROS, and its catalytic activity depends on the binding of metal ions at its active site. Therefore, enhancing the activity of metal-dependent SOD represents a promising strategy to inhibit ferroptosis in cardiomyocytes and alleviate DOX-induced chronic heart failure. In this study, we constructed a biomimetic chiral MnO2 nanozyme co-modified with macrophage and platelet membranes (D/L-MnO2@MM), enabling precise targeting of DOX-injured myocardial tissues. This nanozyme exhibited potent catalase-like and SOD-like activities, efficiently eliminating excessive local hydrogen peroxide (H2O2) and superoxide anions (O2•−). Notably, the D-enantiomeric nanozyme (D-MnO2@MM) significantly enhanced endogenous SOD2 activity via Mn2+ ion release, thereby suppressing the accumulation of lipid peroxides. Furthermore, based on transcriptomic and proteomic analyses, we designed an siRNA targeting the Hmox1 gene (siHmox1) and successfully loaded it onto the nanozyme platform (siHmox1@D/L-MnO2@MM). Both in vitro and in vivo experiments confirmed that the dual mechanism, SOD2 activation and Hmox1 silencing, effectively restored mitochondrial function, attenuated ferroptosis, and significantly improved cardiac function in a rat model of chronic heart failure. Collectively, this study proposes a novel ferroptosis-targeted therapeutic strategy based on a biomimetic chiral nanozyme, offering new insights and promising therapeutic potential for the treatment of DOX-induced cardiotoxicity.
- 1 April 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 58, 203-220
Top Cited PapersOpen AccessChiral metal nanozyme-enabled SOD2 activation and siRNA delivery cooperatively mitigating chronic heart failure
Doxorubicin (DOX) treatment can lead to intracellular iron overload in cardiomyocytes, triggering excessive generation of reactive oxygen species (ROS) and resulting in cardiotoxicity. Superoxide dismutase (SOD) effectively scavenges ROS, and its catalytic activity depends on the binding of metal ions at its active site. Therefore, enhancing the activity of metal-dependent SOD represents a promising strategy to inhibit ferroptosis in cardiomyocytes and alleviate DOX-induced chronic heart failure. In this study, we constructed a biomimetic chiral MnO2 nanozyme co-modified with macrophage and platelet membranes (D/L-MnO2@MM), enabling precise targeting of DOX-injured myocardial tissues. This nanozyme exhibited potent catalase-like and SOD-like activities, efficiently eliminating excessive local hydrogen peroxide (H2O2) and superoxide anions (O2•−). Notably, the D-enantiomeric nanozyme (D-MnO2@MM) significantly enhanced endogenous SOD2 activity via Mn2+ ion release, thereby suppressing the accumulation of lipid peroxides. Furthermore, based on transcriptomic and proteomic analyses, we designed an siRNA targeting the Hmox1 gene (siHmox1) and successfully loaded it onto the nanozyme platform (siHmox1@D/L-MnO2@MM). Both in vitro and in vivo experiments confirmed that the dual mechanism, SOD2 activation and Hmox1 silencing, effectively restored mitochondrial function, attenuated ferroptosis, and significantly improved cardiac function in a rat model of chronic heart failure. Collectively, this study proposes a novel ferroptosis-targeted therapeutic strategy based on a biomimetic chiral nanozyme, offering new insights and promising therapeutic potential for the treatment of DOX-induced cardiotoxicity.
- 20 March 2026
- Vol. 46 (3) , 532-540
[Selenocystine inhibits colon cancer cell growth by promoting reactive oxygen species generation to trigger oxidative damage].
To explore the molecular mechanism by which selenocystine (SeC) inhibits colon cancer cell growth in vitro. Colon cancer cells (RKO, HCT-116, and LoVo) were cultured and treated with 5, 10, or 20 μmol/L SeC for 24 h and 48 h. MTT assay was used to detect the cell viability, and wound healing assay was used to examine changes in cell migration. Flow cytometry with PI staining was used to analyze cell cycle arrest and apoptosis. Fluorescence probes were employed to monitor reactive oxygen species (ROS) generation, mitochondrial morphology and membrane potential, and the changes in ferroptosis were evaluated by detecting malondialdehyde (MDA), glutathione (GSH) and ferrous ion (Fe2+) levels; Western blotting was used to detect the changes in protein expressions. SeC at all the 3 doses significantly inhibited proliferation and migration of colon cancer cells, down-regulated the expression of cell cycle-related proteins CDK2 and CDK4 and activated the apoptotic proteins PARP and caspase-9. Western blotting showed that SeC decreased the expression of ferroptosis proteins FTH1 and xCT and increased the expression of DMT1. The levels of MDA and Fe2+ were increased and GSH level was decreased in SeC-treated cells. Fluorescence staining results showed that SeC treatment induced mitochondrial structure damages and promoted cellular ROS production. SeC treatment also increased phosphorylation of oxidative damage proteins and lowered the expression levels of NRF2 and HO-1 proteins. ROS scavenger significantly reversed the up-regulation of DMT1, PARP and p-H2A.X protein induced by SeC in colon cancer cells. SeC induces apoptosis and ferroptosis of colon cancer cells by promoting ROS generation and initiating oxidative damage, suggesting the potential of SeC as a potential chemotherapeutic agent for colon cancer.
- 20 March 2026
- Vol. 46 (3) , 532-540
[Selenocystine inhibits colon cancer cell growth by promoting reactive oxygen species generation to trigger oxidative damage].
To explore the molecular mechanism by which selenocystine (SeC) inhibits colon cancer cell growth in vitro. Colon cancer cells (RKO, HCT-116, and LoVo) were cultured and treated with 5, 10, or 20 μmol/L SeC for 24 h and 48 h. MTT assay was used to detect the cell viability, and wound healing assay was used to examine changes in cell migration. Flow cytometry with PI staining was used to analyze cell cycle arrest and apoptosis. Fluorescence probes were employed to monitor reactive oxygen species (ROS) generation, mitochondrial morphology and membrane potential, and the changes in ferroptosis were evaluated by detecting malondialdehyde (MDA), glutathione (GSH) and ferrous ion (Fe2+) levels; Western blotting was used to detect the changes in protein expressions. SeC at all the 3 doses significantly inhibited proliferation and migration of colon cancer cells, down-regulated the expression of cell cycle-related proteins CDK2 and CDK4 and activated the apoptotic proteins PARP and caspase-9. Western blotting showed that SeC decreased the expression of ferroptosis proteins FTH1 and xCT and increased the expression of DMT1. The levels of MDA and Fe2+ were increased and GSH level was decreased in SeC-treated cells. Fluorescence staining results showed that SeC treatment induced mitochondrial structure damages and promoted cellular ROS production. SeC treatment also increased phosphorylation of oxidative damage proteins and lowered the expression levels of NRF2 and HO-1 proteins. ROS scavenger significantly reversed the up-regulation of DMT1, PARP and p-H2A.X protein induced by SeC in colon cancer cells. SeC induces apoptosis and ferroptosis of colon cancer cells by promoting ROS generation and initiating oxidative damage, suggesting the potential of SeC as a potential chemotherapeutic agent for colon cancer.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2026 (1)
Selenomethionine Alleviates Spinal Cord Injury by Inhibiting Oxidative Damage–Mediated Neural Apoptosis and Ferroptosis
Spinal cord injury (SCI) as a serious neurological disease remains the great challenge for clinical therapy. Existing studies have confirmed that selenium (Se) supplementation could effectively decrease the risk of neurological diseases, but the mechanism is still unclear. Herein, a mouse SCI model was established, and the potential of selenomethionine (SeMet) against SCI was explored. Behavioral studies showed that SeMet administration in vivo effectively improved the motor symptoms of SCI mice. Mechanism investigation indicated that SeMet administration in vivo significantly blocked the decrease of neurons and Nissl bodies in SCI mice by inhibiting neural apoptosis. SeMet in vivo also dramatically attenuated oxidative damage of SCI mice by regulating the Nrf‐2/Keap‐1 pathway. Further studies revealed that SeMet in vivo significantly alleviated microglia activation and neuroinflammation in SCI mice, as demonstrated by the improved Iba‐1 and inflammatory factors expression, respectively. Moreover, SeMet in vivo apparently inhibited SCI‐induced cell ferroptosis of SCI mice by balancing ferroptosis‐related protein expression. Taken together, the results indicated that oxidative damage–mediated apoptosis and ferroptosis both contributed to the protective potential of SeMet against SCI, which validated the possibility that selenium‐containing agents could be promising drugs for SCI therapy.
- 1 January 2026
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2026 (1)
Open AccessSelenomethionine Alleviates Spinal Cord Injury by Inhibiting Oxidative Damage–Mediated Neural Apoptosis and Ferroptosis
Spinal cord injury (SCI) as a serious neurological disease remains the great challenge for clinical therapy. Existing studies have confirmed that selenium (Se) supplementation could effectively decrease the risk of neurological diseases, but the mechanism is still unclear. Herein, a mouse SCI model was established, and the potential of selenomethionine (SeMet) against SCI was explored. Behavioral studies showed that SeMet administration in vivo effectively improved the motor symptoms of SCI mice. Mechanism investigation indicated that SeMet administration in vivo significantly blocked the decrease of neurons and Nissl bodies in SCI mice by inhibiting neural apoptosis. SeMet in vivo also dramatically attenuated oxidative damage of SCI mice by regulating the Nrf‐2/Keap‐1 pathway. Further studies revealed that SeMet in vivo significantly alleviated microglia activation and neuroinflammation in SCI mice, as demonstrated by the improved Iba‐1 and inflammatory factors expression, respectively. Moreover, SeMet in vivo apparently inhibited SCI‐induced cell ferroptosis of SCI mice by balancing ferroptosis‐related protein expression. Taken together, the results indicated that oxidative damage–mediated apoptosis and ferroptosis both contributed to the protective potential of SeMet against SCI, which validated the possibility that selenium‐containing agents could be promising drugs for SCI therapy.
- Open Access
- 18 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123635
Nanoquadruplex-driven hydrogen therapy: NIR-controlled release for targeted cancer ferroptosis
- 18 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123635
Open AccessNanoquadruplex-driven hydrogen therapy: NIR-controlled release for targeted cancer ferroptosis
- 17 June 2025
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (9) , 1203-1221
Naochuxue formula attenuates early brain injury following subarachnoid hemorrhage by inhibiting neuronal apoptosis via network pharmacology and in vivo experiments
Objectives: Investigate Naochuxue formula’s mechanism in the treatment of subarachnoid hemorrhage. Methods: Analyzed Naochuxue formula’s active components via nontargeted metabolomics, and predicted the core targets using network pharmacology. Sprague‒Dawley rats were randomly divided into six groups: sham, model, Naochuxue formula low, medium and high dose groups, and edaravone. Neurological deficits were assessed using the modified Garcia score and tissue damage was assessed by measuring the brain water content. Blood‒brain barrier permeability was assessed using the Evans blue procedure and pathological changes in the lesion site were observed through HE staining and Nissl staining. TUNEL staining and Caspase-3 immunofluorescence were used to observe the apoptosis of neurons in the hippocampus. The distribution and expression of p-PI3K and p-AKT were determined using immunohistochemistry. The expression of the apoptosis-related genes Caspase-3, Bcl-2, and Bax was determined using RT‒PCR. Key findings: Compared with the model group, rats in the high-dose Naochuxue formula group exhibited significant improvements in neurological defects, brain histopathology, blood‒brain barrier permeability and brain edema on Day 3 posttreatment, downregulated Bax and Caspase-3 expression, and significantly upregulated p-PI3K, p-AKT, and Bcl-2 expression (all P < 0.05). Conclusions: High-dose formula for 3 days activated PI3K/AKT signaling pathway, inhibitd neuronal apoptosis, and exerted neuroprotective effects.
- 17 June 2025
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (9) , 1203-1221
Naochuxue formula attenuates early brain injury following subarachnoid hemorrhage by inhibiting neuronal apoptosis via network pharmacology and in vivo experiments
Objectives: Investigate Naochuxue formula’s mechanism in the treatment of subarachnoid hemorrhage. Methods: Analyzed Naochuxue formula’s active components via nontargeted metabolomics, and predicted the core targets using network pharmacology. Sprague‒Dawley rats were randomly divided into six groups: sham, model, Naochuxue formula low, medium and high dose groups, and edaravone. Neurological deficits were assessed using the modified Garcia score and tissue damage was assessed by measuring the brain water content. Blood‒brain barrier permeability was assessed using the Evans blue procedure and pathological changes in the lesion site were observed through HE staining and Nissl staining. TUNEL staining and Caspase-3 immunofluorescence were used to observe the apoptosis of neurons in the hippocampus. The distribution and expression of p-PI3K and p-AKT were determined using immunohistochemistry. The expression of the apoptosis-related genes Caspase-3, Bcl-2, and Bax was determined using RT‒PCR. Key findings: Compared with the model group, rats in the high-dose Naochuxue formula group exhibited significant improvements in neurological defects, brain histopathology, blood‒brain barrier permeability and brain edema on Day 3 posttreatment, downregulated Bax and Caspase-3 expression, and significantly upregulated p-PI3K, p-AKT, and Bcl-2 expression (all P < 0.05). Conclusions: High-dose formula for 3 days activated PI3K/AKT signaling pathway, inhibitd neuronal apoptosis, and exerted neuroprotective effects.
- 22 November 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-17
Elucidation of the inhibitory effects of Jiedu Yizhi formula on neuronal apoptosis in the treatment of Alzheimer’s disease based on network pharmacology and in vivo experiments
Objective. This study aimed to investigate the mechanism of action of Jiedu Yizhi formula (JDYZF) in the treatment of Alzheimer’s disease (AD) through network pharmacology, molecular docking technology, and in vivo experiments. Method. The main active ingredients of seven herbs in the Chinese Medicine compound JDYZF were identified by searching the TCMSP database, PubChem database, CNKI, and other sources. Disease targets of AD were obtained from databases such as OMIM, TDD, DisGeNET, and DrugBank. A protein‒protein interaction (PPI) network was constructed using the STRING platform, and core targets were identified through topological analysis using Cytoscape software. Gene Ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the relevant targets were performed using the Metascape database. The main active ingredients of JDYZF and potential core targets were identified based on degree values. Molecular docking technology was used to verify the interactions between the main active ingredients and potential core targets. Furthermore, water maze tests and hematoxylin-eosin (HE) staining of brain and liver tissues were performed to evaluate the effects of JDYZF on cognitive dysfunction in AD mice and neuronal damage in hippocampal brain tissue and to assess drug toxicity. PCR was performed to determine the expression levels of the apoptosis-related genes Bcl-2, Bax, and caspase-3 and to investigate the effect of JDYZF on hippocampal apoptosis in AD mice. Results. One hundred twelve core PPI target proteins, including CASP3, TP53, and VEGFA, were found between JDYZF and AD. The KEGG pathway enrichment analysis showed significant enrichment of the MAPK signaling pathway, PI3K/AKT signaling pathway and so on. Water maze tests revealed that the high-dose JDYZF treatment significantly improved the escape latency of AD model mice. The HE staining results showed that JDYZF exerted a protective effect on neuronal damage in the hippocampus of AD mice. JDYZF could upregulate the expression of the anti-apoptotic factor Bcl-2 while downregulating the expression of the proapoptotic factors Bax and caspase-3. Conclusion. JDYZF can improve the cognitive function of AD mice by suppressing cell apoptosis.
- 22 November 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-17
Elucidation of the inhibitory effects of Jiedu Yizhi formula on neuronal apoptosis in the treatment of Alzheimer’s disease based on network pharmacology and in vivo experiments
Objective. This study aimed to investigate the mechanism of action of Jiedu Yizhi formula (JDYZF) in the treatment of Alzheimer’s disease (AD) through network pharmacology, molecular docking technology, and in vivo experiments. Method. The main active ingredients of seven herbs in the Chinese Medicine compound JDYZF were identified by searching the TCMSP database, PubChem database, CNKI, and other sources. Disease targets of AD were obtained from databases such as OMIM, TDD, DisGeNET, and DrugBank. A protein‒protein interaction (PPI) network was constructed using the STRING platform, and core targets were identified through topological analysis using Cytoscape software. Gene Ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the relevant targets were performed using the Metascape database. The main active ingredients of JDYZF and potential core targets were identified based on degree values. Molecular docking technology was used to verify the interactions between the main active ingredients and potential core targets. Furthermore, water maze tests and hematoxylin-eosin (HE) staining of brain and liver tissues were performed to evaluate the effects of JDYZF on cognitive dysfunction in AD mice and neuronal damage in hippocampal brain tissue and to assess drug toxicity. PCR was performed to determine the expression levels of the apoptosis-related genes Bcl-2, Bax, and caspase-3 and to investigate the effect of JDYZF on hippocampal apoptosis in AD mice. Results. One hundred twelve core PPI target proteins, including CASP3, TP53, and VEGFA, were found between JDYZF and AD. The KEGG pathway enrichment analysis showed significant enrichment of the MAPK signaling pathway, PI3K/AKT signaling pathway and so on. Water maze tests revealed that the high-dose JDYZF treatment significantly improved the escape latency of AD model mice. The HE staining results showed that JDYZF exerted a protective effect on neuronal damage in the hippocampus of AD mice. JDYZF could upregulate the expression of the anti-apoptotic factor Bcl-2 while downregulating the expression of the proapoptotic factors Bax and caspase-3. Conclusion. JDYZF can improve the cognitive function of AD mice by suppressing cell apoptosis.
- 28 February 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (4) , 625-633
Methylseleninic acid inhibits human glioma growth in vitro and in vivo by triggering ROS-dependent oxidative damage and apoptosis
Selenium-containing agents showed novel anticancer activity by triggering pro-oxidative mechanism. Studies confirmed that methylseleninic acid (MeSe) displayed broad-spectrum anti-tumor activity against kinds of human cancers. However, the anticancer effects and mechanism of MeSe against human glioma growth have not been explored yet. Herein, the present study showed that MeSeA dose-dependently inhibited U251 and U87 human glioma cells growth in vitro. Flow cytometry analysis indicated that MeSe induced significant U251 cells apoptosis with a dose-dependent manner, followed by the activation of caspase-7, caspase-9 and caspase-3. Immunofluorescence staining revealed that MeSe time-dependently caused reactive oxide species (ROS) accumulation and subsequently resulted in oxidative damage, as convinced by the increased phosphorylation level of Ser428-ATR, Ser1981-ATM, Ser15-p53 and Ser139-histone. ROS inhibition by glutathione (GSH) effectively attenuated MeSe-induced ROS generation, oxidative damage, caspase-3 activation and cytotoxicity, indicating that ROS was an upstream factor involved in MeSe-mediated anticancer mechanism in glioma. Importantly, MeSe administration in nude mice significantly inhibited glioma growth in vivo by inducing apoptosis through triggering oxidative damage. Taken together, our findings validated the possibility that MeSe as a selenium-containing can act as potential tumor chemotherapy agent for therapy of human glioma.
- 28 February 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (4) , 625-633
Methylseleninic acid inhibits human glioma growth in vitro and in vivo by triggering ROS-dependent oxidative damage and apoptosis
Selenium-containing agents showed novel anticancer activity by triggering pro-oxidative mechanism. Studies confirmed that methylseleninic acid (MeSe) displayed broad-spectrum anti-tumor activity against kinds of human cancers. However, the anticancer effects and mechanism of MeSe against human glioma growth have not been explored yet. Herein, the present study showed that MeSeA dose-dependently inhibited U251 and U87 human glioma cells growth in vitro. Flow cytometry analysis indicated that MeSe induced significant U251 cells apoptosis with a dose-dependent manner, followed by the activation of caspase-7, caspase-9 and caspase-3. Immunofluorescence staining revealed that MeSe time-dependently caused reactive oxide species (ROS) accumulation and subsequently resulted in oxidative damage, as convinced by the increased phosphorylation level of Ser428-ATR, Ser1981-ATM, Ser15-p53 and Ser139-histone. ROS inhibition by glutathione (GSH) effectively attenuated MeSe-induced ROS generation, oxidative damage, caspase-3 activation and cytotoxicity, indicating that ROS was an upstream factor involved in MeSe-mediated anticancer mechanism in glioma. Importantly, MeSe administration in nude mice significantly inhibited glioma growth in vivo by inducing apoptosis through triggering oxidative damage. Taken together, our findings validated the possibility that MeSe as a selenium-containing can act as potential tumor chemotherapy agent for therapy of human glioma.
- Open Access
- 9 February 2024
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2024, 1-11
Selenium-Containing Protein from Selenium-Enriched Spirulina platensis Relieves Osteoporosis by Inhibiting Inflammatory Response, Osteoblast Inactivation, and Osteoclastogenesis
Osteoporosis (OP) is a systemic bone disease with loss of bone mass and destruction of the microscopic structure. Many antiosteoporosis drugs have been used for OP therapy, but the therapeutic efficiency remains limited. Therefore, there is an urgent need to develop new drugs for antiosteoporosis treatment. Selenium (Se) is one kind of essential trace element for humans and displays pivotal roles in maintaining bone homeostasis. However, the modulation roles of Se are greatly affected by its chemical forms. Herein, Se containing protein derived from Se-enriched Spirulina platensis (Se-SP) were extracted and used for the treatment of OP in an ovariectomized mice model. The results showed that Se-SP showed enhanced potential in promoting excretion of calcium and alkaline phosphatase (ALP) expression than that of SP in MC3T3-E1 cells. Micro-CT revealed that Se-SP administration in vivo effectively alleviated bone loss as indicated by the upregulated BV, Tb.Th, Bv/TV, Tb.N, and BMD as well as the decreased Tb.Sp. Se-SP in vivo also significantly suppressed inflammatory response through restricting the expression of proinflammatory cytokines expression and upregulating the secretion of anti-inflammatory cytokines. Additionally, Se-SP effectively inhibited ovariectomy-induced osteoblast inactivation and osteoclastogenesis by upregulating BMP2, RUNX2, COL-I, OCN and OPG pression and downregulating RANKL expression. Together, these findings suggested that Se-SP was a new form of Se in therapy of human OP.
- 9 February 2024
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2024, 1-11
Open AccessSelenium-Containing Protein from Selenium-Enriched Spirulina platensis Relieves Osteoporosis by Inhibiting Inflammatory Response, Osteoblast Inactivation, and Osteoclastogenesis
Osteoporosis (OP) is a systemic bone disease with loss of bone mass and destruction of the microscopic structure. Many antiosteoporosis drugs have been used for OP therapy, but the therapeutic efficiency remains limited. Therefore, there is an urgent need to develop new drugs for antiosteoporosis treatment. Selenium (Se) is one kind of essential trace element for humans and displays pivotal roles in maintaining bone homeostasis. However, the modulation roles of Se are greatly affected by its chemical forms. Herein, Se containing protein derived from Se-enriched Spirulina platensis (Se-SP) were extracted and used for the treatment of OP in an ovariectomized mice model. The results showed that Se-SP showed enhanced potential in promoting excretion of calcium and alkaline phosphatase (ALP) expression than that of SP in MC3T3-E1 cells. Micro-CT revealed that Se-SP administration in vivo effectively alleviated bone loss as indicated by the upregulated BV, Tb.Th, Bv/TV, Tb.N, and BMD as well as the decreased Tb.Sp. Se-SP in vivo also significantly suppressed inflammatory response through restricting the expression of proinflammatory cytokines expression and upregulating the secretion of anti-inflammatory cytokines. Additionally, Se-SP effectively inhibited ovariectomy-induced osteoblast inactivation and osteoclastogenesis by upregulating BMP2, RUNX2, COL-I, OCN and OPG pression and downregulating RANKL expression. Together, these findings suggested that Se-SP was a new form of Se in therapy of human OP.
- 29 November 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (2) , 263-282
Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease
- 29 November 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (2) , 263-282
Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease